6515--Oncology Reagents

THIS REQUEST FOR INFORMATION (RFI) IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES ONLY AND DOES NOT CONSTITUTE A SOLICITATION.

THE SUBMISSION OF PRICING, CAPABILITIES FOR PLANNING PURPOSES, AND OTHER MARKET INFORMATION IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI IN ACCORDANCE WITH (IAW) FAR 15.201(e).

DISCLAIMER

This RFI is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.

SOURCES SOUGHT DESCRIPTION

This is NOT a solicitation announcement. This is a sources sought/RFI only. The purpose of this sources sought/RFI is to gain knowledge of potential qualified sources and their size classification relative to NAICS 325413 (size standard of 1250 Employees). Responses to this sources sought will be used by the Government to make appropriate acquisition decisions. After reviewing the responses to this sources sought, a solicitation announcement may be published. Responses to this sources sought synopsis are not considered adequate responses for a solicitation announcement.

The Department of Veterans Affairs (VA), VISN 22 Network Contracting Office, is seeking sources that can provide oncology supplies and reagents that at a minimum meet the following salient characteristics with a brand name or equal product for the Greater Los Angeles VA Healthcare System:

Reagents must be capable of detecting the wild type (Negative) from Mutated (Positive) genes

Reagents must be capable of testing DNA extracted from whole blood or bone marrow samples using a reverse transcription-polymerase chain reaction (RT-PCR) based method, or High-Resolution Melt (HRM) Analysis

Reagents must be capable of determining DNA quantity by measuring the optical density (OD) of the sample at 260 nm.

Resultant DNA must be capable of being be diluted to a concentration of 5 ng/µl in 1x TE buffer* at pH 8.0

Resultant DNA must be capable of being stored at +4 to +8°C for 1 week or at 20°C if longer term storage is required.

The real-time (qPCR) reaction must be optimized for DNA samples containing 25 ng purified genomic DNA.

The limit of detection (LOD) shall be 0.061%

Reagents must be capable of being stored at -15 C to -30 C

The reagent shelf life must be a minimum of one year upon receipt by the laboratory.

Brand name Info:

BRAND

PRODUCT DESCRIPTION

PRODUCT #

Quantity

Ipsogen

JAK2 MutaQuant Kit

673513

77 (kits contain 24 reagents)

The information identified above is intended to be descriptive, not restrictive and to indicate the quality of the supplies/services that will be satisfactory. It is the responsibility of the interested source to demonstrate to the government that the interested parties can provide the supplies/services that fulfill the required specifications.

If you are interested, and are capable of providing the sought out supplies/services, please provide the requested information as well as the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions:

(1) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran Owned Small Business (SDVOSB), Veteran Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc.)

(2) Is your company considered small under the NAICS code identified under this RFI?

(3) Are you the manufacturer or distributor of the items being referenced above (or equivalent product/solution)? What is the manufacturing country of origin of these items?

(4) If you re a small business and you are an authorized distributor/reseller for the items identified above (or equivalent product/solution), do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified?

(5) Does your company have an FSS contract with GSA or the NAC or are you a contract holder with NASA SEWP or any other federal contract? If so, please provide the contract type and number.

(6) If you are an FSS GSA/NAC or NASA SEWP contract holder or other federal contract holder, are the referenced items/solutions available on your schedule/contract?

(7) Please provide general pricing for your products/solutions for market research purposes.

(8) Please state your company s DUNS number.

(9) Please submit your capabilities in regard to the salient characteristics being provided and any information pertaining to equal to items to establish capabilities for planning purposes?

*** Submissions addressing Section (9) should show clear, compelling and convincing*** evidence that all equal to items" meet all required salient characteristics.

Responses to this notice shall be submitted via email to Kahlfanie.Carabon@va.gov. Telephone responses shall not be accepted. Responses must be received no later than Friday, May 1st, 2026, at 3:00 P.M. Pacific Time. If a solicitation is issued it shall be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this request for information. Responses to this notice are not a request to be added to a prospective bidders list or to receive a copy of the solicitation.